Connect with us

Science

Birds That Build Nests With Domes May Be Doomed

Published

on

Birds That Build Nests With Domes May Be Doomed

Lots of the fowl nests you’ll spot this spring could have the acquainted open and cupped form, excellent for securing eggs and finally hatchlings. About 30 p.c of fowl species are the starchitects of the avian kingdom, setting up elaborate domed nests with roofs. Whereas ecologists have lengthy thought that domed nests supplied higher security from predators and climate, a brand new examine suggests songbirds who go for less complicated nests could also be higher off in the long term.

Nearly all songbirds may be traced to Australasia round 45 million years in the past, when Australia was connected to Antarctica and coated by lush forests as an alternative of parched deserts. Statistical analyses of songbirds’ traits and evolution discovered domed nests have been the “ancestral structure” of songbirds’ properties. However domed nests have been then deserted in favor of less complicated cup designs when songbirds started spreading round the remainder of the world some 40 million years in the past.

Evolutionary biologists, like Iliana Medina of the College of Melbourne, questioned why domed nests have been deserted by so many fashionable birds, and why solely a 3rd of birds construct them as we speak. To reply that, she and her colleagues examined the ecological success of dome builders in contrast with cup builders, then tied these knowledge to their evolutionary historical past.

For over 3,100 songbird species, Dr. Medina and colleagues gathered as a lot knowledge as they might discover: how huge the birds’ our bodies and ranges are, their latitude and elevation, whether or not they reside in cities and, after all, what sort of nests they construct. All this data was crucial as a result of many elements affect how profitable a species is, and Dr. Medina needed to house in on nest kind as exactly as potential.

Her analyses, printed final month within the journal Ecology Letters, revealed shocking patterns. Songbirds that construct domed nests are likely to have smaller ranges, with stricter climatic wants. If domed nests provide higher safety, some ecologists had thought, that would permit birds’ ranges to increase and face up to broader situations. Dr. Medina’s outcomes contradict that pondering.

Advertisement

Primarily based on the findings, Dr. Medina proposes that dome builders is perhaps much less adaptable than cup builders. Although domed nests provide higher safety from the weather, in addition they are usually bigger — simpler for a predator to identify. Larger nests additionally take extra time to construct and require extra supplies, probably limiting each when and the place they may very well be constructed and making birds much less more likely to go away an imperiled habitat, like a sunk-cost fallacy with feathers.

“Possibly it’s truly higher to have a disposable, low-cost nest you can construct a number of instances a season,” stated Jordan Value, an evolutionary biologist at St. Mary’s School of Maryland who was not concerned within the examine. “You’re uncovered to the weather, however you possibly can escape predators actually rapidly.”

The analysis additionally confirmed that dome builders are much less more likely to reside in cities, maybe due to a scarcity of appropriate nesting websites, a dearth of constructing supplies and even as a result of cities are usually hotter. Dome builders additionally take longer to construct nests, an intuitive discovering that had not been supported by a world evaluation till now.

Dr. Medina then peered again in time, modeling the pure historical past of nest-building traits and new species over songbirds’ roughly 45-million-year historical past. She discovered dome builders had barely greater extinction charges than cup builders, a consequence opposite to notions that domed nests have been most secure.

“The associated fee-benefit evaluation of constructing both an open-cup nest or a dome nest modified in some unspecified time in the future,” Dr. Value stated. “Some species saved their outdated methods, and a few innovated one thing new, which allowed them to actually flourish.” What prompted the change of value, nevertheless, stays unknown; new parasites or predators may have arrived, or climates may have modified.

Advertisement

In the present day, dome builders face new challenges posed by people, together with variable climates, habitat loss and constructed environments. Birds, like many different fauna, are experiencing accelerating charges of extinction.

“There aren’t any actual administration actions we are able to do concerning the nest of a species,” stated James Mouton, a postdoctoral fellow on the Smithsonian Migratory Hen Middle who was not concerned within the examine. “It’s not one thing we are able to coach them in.” However conservation efforts may assist restore and shield necessary dome-nester habitats, bolstering probably susceptible populations.

“There are some fairly historic lineages, some birds that branched off the songbird tree actually early,” Dr. Value stated. “We have to look out for these species.”

He added, “A few of these dome-nesting species, it could be horrible to lose.”

Advertisement
Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Science

Opinion: Long COVID is solvable, but we need more clinical trials

Published

on

Opinion: Long COVID is solvable, but we need more clinical trials

We are living in an epidemic of chronic disease, with a growing number of pesticides, chemicals and food additives implicated in the declining health of Americans. Since 2019, another factor has been at play as well: The SARS-CoV-2 virus has driven a huge increase in chronic health consequences, broadly referred to as long COVID.

Infection by the COVID-19 virus is a consequential new variable in our nation’s health that can substantially increase the incidence of serious conditions such as neurological disease, heart attack and stroke. Approximately 6% of U.S. adults suffer from long COVID — at a cost to our economy estimated at $3.7 trillion a year.

Contrary to what is often portrayed in the media, long COVID is not a mystery. There is a straightforward reason at least some people may remain ill “after COVID”: They still have the SARS-CoV-2 virus — or parts of the virus — in their bodies. For example, one team found that almost two years after infection, long COVID patients had not yet cleared the virus from their gut tissue. These persistent viral reservoirs appear to leak spike protein — the part of the virus that gives coronaviruses their distinctive “crown” appearance — into blood circulation, potentially driving inflammation of the brain and other organs, and increasing health consequences such as heart disease.

While early efforts are underway to help clear persistent viral reservoirs, more well-designed clinical trials are desperately needed to help the millions suffering from long COVID return to normal life. To address this emergency, we formed a global consortium of scientists to accelerate research, including by publishing a recent roadmap for testing medications aimed at clearing persistent SARS-CoV-2. Our proposal draws on successful approaches from cancer research and treatment strategies used against other viral infections such as HIV and hepatitis C; these histories offer lessons about trial design, drug candidates and how to develop tests for persistent viral reservoirs.

The most promising trials may also be among the most complex to carry out, because they may combine medications targeting the virus — such as antiviral drugs and monoclonal antibodies — with treatments to activate immune cells. It may also be important to simultaneously address other problems associated with long COVID, such as immune dysfunction and microbiome changes.

Advertisement

To add another variable to these complex trials we do not yet know the duration of treatment each type of medication might need. For example, current long COVID clinical trials are testing 5 to 15 days of antivirals like Paxlovid. But treatment of persistent hepatitis C virus requires 8 to 12 weeks of antiviral therapy. In cats with feline infectious peritonitis — also caused by a persistent coronavirus — 12 weeks of antiviral treatment is required for effective treatment. Such an extended approach may require careful studies to test the safety of potential long COVID medications when given for longer periods of time.

All of this will be an interdisciplinary global undertaking. But the effort is worth it.

The looming question now is: Who will pay for drug development and trials? Big pharmaceutical companies can afford to run trials, and they should. But small biotech companies do not have the same resources. Already, because of this limitation, multiple antivirals and monoclonal antibodies with the potential to help long COVID patients are sitting on shelves rather than being studied in patients who urgently need more options.

Government and private funding should solve that by helping smaller companies run early-stage trials. These programs, which must be agile and adaptive and continually incorporate the real-world experience of patients into their design, are ideal for “high-risk, high-reward” agencies like the Advanced Research Projects Agency for Health, which is part of Health and Human Services. It was therefore encouraging to hear Robert F. Kennedy Jr., who is now the secretary of Health and Human Services, say during his recent confirmation hearing that he would enthusiastically work with Congress to direct long COVID funding toward much-need clinical trials.

If public funding supports the development of any new long COVID drug, the data and resulting therapies should be open source and available to manufacturers of generics, which will increase trust in the treatments and will benefit patients across the globe.

Advertisement

The world has been in this position before, when facing HIV in the late 1980s and early 1990s. A combination of rapid government and private funding made multiple companies more willing to engage in drug development. There are now more than 25 approved drugs for HIV infection. The development of these treatments transformed HIV from a life-threatening infection to a manageable chronic condition — for those with access to the medications. In some cases, public support compelled otherwise-competing drug companies to work together for a greater good.

Lessons learned from fighting SARS-CoV-2 could also help scientists in the battles against other conditions, because long COVID is just one of many chronic disease states that start with an infection. Others include chronic or post-treatment Lyme disease, myalgic encephalomyelitis and post-dengue fatigue syndrome. Persistent viral infection is also increasingly being documented among Alzheimer’s and multiple sclerosis patients.

The urgency of long COVID is a call to arms for government and private funders to help bring medications and protocols to the people who need them. Ultimately, far more may benefit from the knowledge gained.

Amy D. Proal, a microbiologist, is a founder of the PolyBio Research Foundation, a nonprofit that supports research into the root cause drivers of chronic disease.

Advertisement
Continue Reading

Science

NIH Research Grants Lag Behind Last Year’s by $1 Billion

Published

on

NIH Research Grants Lag Behind Last Year’s by  Billion

Federal research funding to tackle areas like cancer, diabetes and heart disease is lagging by about $1 billion behind the levels of recent years, reflecting the chaotic start of the Trump administration and the dictates that froze an array of grants, meetings and communications.

The slowdown in awards from the National Institutes of Health has been occurring while a legal challenge plays out over the administration’s sudden policy change last week to slash payments for administrative and facilities costs related to medical research. A federal judge in Massachusetts has temporarily blocked the cutbacks, pending hearings later this month.

Federally funded research has driven major advances in cutting-edge gene therapies and immune-system-boosting treatments for certain cancers, cystic fibrosis and sickle cell disease.

The broader lag in funding is being felt at universities and medical centers from Baton Rouge to Boston, according to congressional lawmakers who are tracking it. Federal spending records show the allocations are about $1 billion lower than last year’s disbursements were at this time.

N.I.H. funding has ground to a halt in the past 10 days, according to Senator Tammy Baldwin, Democrat of Wisconsin.

Advertisement

“The president has completely stopped funding for research that discovers cures for diseases that devastate families across the country, like cancer and Alzheimer’s disease, all so he can give tax breaks to billionaires and big corporations,” Ms. Baldwin said in a statement on Friday. “Make no mistake, their efforts to rob Peter to pay Paul means crushing families’ hopes and dreams of having cures.”

It was not clear whether the stalled funding reflected an administrative backlog or efforts by Trump officials to defy the rulings of judges who have temporarily quashed efforts to freeze federal grant-making and spending.

In the first six weeks of 2024, the N.I.H. awarded more than 11,000 grants amounting to roughly $2.5 billion. During the same time period this year, the agency doled out about $1.4 billion, a figure hundreds of millions of dollars lower than the amount awarded within this period for the last six years. The agency issued about $36 billion in grants last year.

Some administration officials have criticized the research grants, saying they reflect a liberal bias and are dedicated to diversity and equity efforts. Some critics also contend that certain universities receive far larger outlays to cover overhead costs than other institutions.

A spokeswoman for the N.I.H. did not immediately return a request for comment.

Advertisement

Earlier this week, Senator Patty Murray, Democrat of Washington, tried to add a provision to a budget bill that would have restored the N.I.H. funding to agreed-upon levels. The effort failed on a party-line vote.

“Trump and Elon — either through sheer ignorance or a genuine lack of caring — are putting lifesaving research in America on life support,” she said in a statement, referring to the billionaire Elon Musk.

The N.I.H. has undergone considerable turmoil in recent days, with two high-ranking officials announcing sudden departures. The agency has no permanent leader in place yet, though Jay Bhattacharya, the Trump administration nominee and a Stanford professor, has begun to make the rounds in Congress as his confirmation hearings approach.

Robert F. Kennedy Jr., the secretary of the top federal health agency, has said he wants to back off on infectious disease research, a core N.I.H. study area, and focus instead on chronic diseases, which the agency also studies. The agency has 27 separate institutes and centers that fund studies and develop treatments for diseases like cancer and heart conditions as well as infectious diseases like AIDS and Covid.

Meetings at the agency — during which experts review grant applications and make funding recommendations — were abruptly canceled at the end of January after the new administration issued a sweeping communications ban, effectively halting the funding of new research. Some of those meetings have since resumed. The White House budget office also ordered a pause on all federal grants, which it rescinded days later.

Advertisement

The proposed cuts to indirect costs to medical research alone have been enough to raise deep concerns at Dartmouth and at other institutions.

“If the federal government cuts its investment, we will have to scale back on research, and cutting-edge science will be cut short,” Dean Madden, the vice provost for research at Dartmouth’s medical school, said at a news conference on Friday. “You don’t know what discoveries won’t be made as a result, but they might include a cure for some childhood cancer or treatment for Alzheimer’s or dozens of other diseases that are afflicting patients across our country.”

Continue Reading

Science

Texas County Declares an Emergency Over Toxic Fertilizer

Published

on

Texas County Declares an Emergency Over Toxic Fertilizer

A Texas county is taking steps to declare a state of emergency and seek federal assistance over farmland contaminated with harmful “forever chemicals,” as concerns grow over the safety of fertilizer made from sewage.

Johnson County, south of Fort Worth, has been roiled since county investigators found high levels of chemicals called PFAS, or per- and polyfluoroalkyl substances, at two cattle ranches in the county in 2023.

The county says the PFAS, also known as forever chemicals because they don’t break down in the environment, came from contaminated fertilizer used on a neighboring farm. That fertilizer was made out of treated sewage from Fort Worth’s wastewater treatment plant. A New York Times investigation into the use of contaminated sewage sludge as fertilizer focused in part on the experience of ranchers in Johnson County.

PFAS, which is used in everyday items like nonstick cookware and stain-resistant carpets, has been found to increase the risk of certain types of cancer, and can cause birth defects, developmental delays in children, and other health harms.

County commissioners passed a resolution this week calling on Texas governor Greg Abbott to join the declaration, and seek federal disaster assistance.

Advertisement

“This is uncharted territory,” said Larry Woolley, one of the county’s four commissioners, in an interview. The funds, he said, would be put toward testing and monitoring of drinking water, cleanup, as well as euthanization of cattle contaminated from the soil, crops and water.

Johnson county is also pressing the state of Texas to block the use of sewage sludge to fertilize local farmland. “Ultimately, our goal is to stop the flow of contaminants into the county,” said Christopher Boedeker, a county Judge.

For decades, farmers nationwide have been encouraged by the federal government to use treated sewage sludge as fertilizer for its rich nutrients, and to reduce the amount of sludge that must be buried in landfills or incinerated. Spreading sewage on farmland also cuts down on the use of fertilizers made from fossil fuels.

But a growing body of research shows that the black sludge, made from the sewage that flows from homes and factories, can contain heavy concentrations of PFAS as well as other harmful contaminants.

Last month, under the Biden administration, the Environmental Protection Agency for the first time warned that PFAS-tainted sewage sludge used as fertilizer can contaminate the soil, groundwater, crops and livestock, posing human health risks.

Advertisement

The Biden administration also set drinking-water standards for certain kinds of PFAS and designated two of the chemicals as hazardous substances that must be cleaned up under the nation’s Superfund law. The future of those measures is uncertain under the Trump administration. The E.P.A. says there is no safe level of exposure to those two PFAS.

There has been little testing on farms. Maine is the only state that has started to systematically test farmland for PFAS, and has shuttered dozens of dairy farms found with contamination.

Johnson County is the first to directly seek federal assistance. It remained unclear, however, exactly how the county could tap federal funds, particularly amid the Trump administration’s freeze on federal spending.

President Biden’s Bipartisan Infrastructure Law had provided $2 billion in funding to address PFAS and other contaminants in drinking water. It is the future of funds like these, which must be requested at the state level, that remain uncertain in the new administration.

The Federal Emergency Management Agency also has funds available for well testing, which must be requested by states, though that money is typically distributed after natural disasters. President Trump has also targeted FEMA funding, saying he wants states to handle disasters without the federal agency’s help. The Department of Agriculture also offers assistance to farmers affected by PFAS contamination, but that program is currently limited to dairy farmers.

Advertisement

That leaves Johnson County in a bind.

While President Trump has been hostile to regulations, he also spoke on the campaign trail of “getting dangerous chemicals out of our environment.” And concerns about PFAS contamination have reached some deeply red states and counties, like Johnson County, which voted overwhelmingly for Mr. Trump.

The E.P.A. and FEMA did not provide comment.

In December, Texas attorney general Ken Paxton sued the largest PFAS makers, saying they knew about the dangers of these chemicals, but continued to market their use. The G.O.P.-controlled Texas state legislature is considering bills that set limits on PFAS in sludge fertilizer and require producers to test for the chemicals.

The state of Texas has not indicated whether they will back Johnson County’s declaration and support its request for federal assistance. The governor’s office did not respond to requests for comment.

Advertisement

Ricky Richter, a spokesman at the state’s environmental regulator, the Texas Commission of Environmental Quality, said the agency’s own analysis of PFAS levels discovered by Johnson County investigators did not suggest any harm to human health or the environment.

The agency did not immediately provide details of its analysis.

Johnson county officials said they stood behind their findings. The ranchers are suing the fertilizer provider, alleging that the contamination on their land was slowly sickening and killing their livestock. They are still caring for the surviving cattle, but are no longer sending them to market.

Continue Reading

Trending